This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The evidence was derived from a review or synthesis of completed studies and estimates based on authors' assumptions.
Modelling
A Markov (state transition) decision model was used to simulate the progression of patients with Type 2 diabetes. The model was described in detail. The disease states modelled were microalbuminuria, early overt nephropathy, advanced overt nephropathy, doubling of serum creatinine (DSC), ESRD treated with dialysis, ESRD treated with renal transplant, and death. A distinction was made between early and advanced overt nephropathy to bridge the gap that existed between patients reaching the end point of the IRMA-2 study and patients included in the IDNT trial (Lewis et al. 2001 , see 'Other Publications of Related Interest' below for bibliographic details). The cohort was followed yearly over a 25-year horizon.
Outcomes assessed in the review
The parameters used in the model included:
the annual transition probabilities for disease state progression;
the age-and gender-specific all-cause mortality rates adjusted by state-dependent relative risks (RRs) for all-cause mortality in each state; and the ESRD outcome data, including mortality rates in the ESRD states.
Study designs and other criteria for inclusion in the review
The authors used randomised controlled trials (RCTs), cohort studies and published literature.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two RCTs supplied much of the data.
Methods of combining primary studies
A narrative method was used to combine the studies.
Investigation of differences between primary studies
The authors justified their choice of the comparators used. Several trials have recently reported on the blood pressureindependent renoprotective effects of angiotensin-receptor antagonist treatment on the progression of various stages of renal disease in patients with hypertension and Type 2 diabetes. These trials showed that renal events could be postponed considerably, which could have impacts on both life expectancy and health care costs. You should judge whether these strategies are relevant in your own setting, or whether other comparators could also be relevant (e.g. ACE inhibitors or others drug members of the irbesartan class).
Validity of estimate of measure of effectiveness
The main source of the effectiveness evidence was two trials (Parving et al. 2001 and Lewis et al. 2001) . Much of the effectiveness evidence was derived from these two trials and studies from different countries, which were adequate sources. However, it was unclear whether a systematic review of the literature had been undertaken. Although this is common practice with models, it does not always ensure that the best data available are used in the model. The authors used data from the available studies selectively. One cannot be sure that all relevant literature was identified, although it is certain that RCTs were used to derive the effectiveness of the strategies. The estimates of effectiveness were derived credibly from the studies identified. The authors used data from published sources and their own assumptions, justifying their assumptions with reference to the medical literature. The estimates were investigated in sensitivity analyses, using ranges from the literature.
